Tissue Total RNA, Colon: right
Specifications
| Product Data | |
| Disease State | Cancer |
|---|---|
| Diagnosis Category | Colorectal Cancer |
| Sample ID | FR5B33F094 |
| Case ID | CI0000010668 |
| Prep | 1 |
| Vial ID | RN00002EB2 |
| Tissue of Origin | Colon: right |
| Site of Finding | Colon: right |
| Appearance | Tumor |
| Sample Diagnosis (from Pathology Verification) | Adenocarcinoma of colon |
| Normal | 0% |
| Lesional | 0% |
| Tumor | 70% |
| Tumor Hypo/Acellular Stroma | 20% |
| Tumor Hypercellular Stroma | 10% |
| Necrosis | 0% |
| T (Extent of Primary Tumor) | T2 |
| N (Lymph node metastasis) | N0 |
| M (Distant metastasis) | MX |
| CASE Diagnosis (from medical center path report) | Adenocarcinoma of colon |
| Age | 76 |
| Gender | Male |
| Tumor Grade | AJCC G1: Well differentiated |
| Minimum Stage Grouping | I |
| Storage | Store tissue total RNA at -80°C. |
| Stability | These products are stable for one year from date of shipping when stored at -80°C without repeated freeze/thaws. |
| Shipping | Dry Ice |
Reviews
Documents
| Datasheet | |
| SDS | |
Citations
Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes
Ragulan, Eason, Fontana et al
Sci Rep (2019) 9 (1), 7665 DOI: 10.1038/s41598-019-43492-0
Ragulan, Eason, Fontana et al
Sci Rep (2019) 9 (1), 7665 DOI: 10.1038/s41598-019-43492-0
AI Summary: OriGene contributed to this study by providing a cohort of 17 colorectal cancer RNA samples ("RNA samples (OriGene; n = 17)") that were used to validate the NanoCRCA biomarker assay for molecular subtyping.
Snippet: and FFPE. The first included RNA samples from 17 stage IV patients (Montpellier cohort) from a published study 4 . A second cohort of RNA samples (OriGene;n = 17) was purchased from OriGene (Rockville, MD, USA). A third
A Low-Cost Multiplex Biomarker Assay Stratifies Colorectal Cancer Patient Samples into Clinically-Relevant Subtypes
Ragulan, Eason, Nyamundanda et al
bioRxiv (2017)
Ragulan, Eason, Nyamundanda et al
bioRxiv (2017)
Snippet: GEO accession GSE101588. As an additional cohort (OriGene) is commercially available total RNA from 16 primary CRC tumours and 1 liver metastasis purchased from OriGene ... cohorts (Montpellier and OriGene;see Materials & Methods;Table S2a). The distribution ... Cite SaveSaving
Showing 1-2 of 2 papers.
Powered by BizGenius
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen
complexities in the preparation of your product. International customers may expect an additional 1-2 weeks
in shipping.
Related Products
- Price:
- Actual Price:
Welcome to OriGene AI!
I'm your AI-powered guide to everything OriGene.
Ask me anything:
- Product specs
- Ordering help
- Technical questions
- How to find exactly what your experiment needs
Prefer a live agent? Connect with us by clicking the green chat icon, as seen in the image below or email our team at custsupport@origene.com.
